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Abstract
Currently, the clinical diagnosis of schizophrenia relies solely on self-reporting and clinical interview, and likely
comprises heterogeneous biological subsets. Such subsets may be deﬁned by an underlying biology leading to solid
biomarkers. A transgenic rat model modestly overexpressing the full-length, non-mutant
Disrupted-in-Schizophrenia 1 (DISC1) protein (tgDISC1 rat) was generated that deﬁnes such a subset, inspired by our
previous identiﬁcation of insoluble DISC1 protein in post mortem brains from patients with chronic mental illness.
Besides speciﬁc phenotypes such as DISC1 protein pathology, abnormal dopamine homeostasis, and changes in
neuroanatomy and behavior, this animal model also shows subtle disturbances in overarching signaling pathways
relevant for schizophrenia. In a reverse-translational approach, assuming that both the animal model and a patient
subset share common disturbed signaling pathways, we identiﬁed differentially expressed transcripts from peripheral
blood mononuclear cells of tgDISC1 rats that revealed an interconnected set of dysregulated genes, led by decreased
expression of regulator of G-protein signaling 1 (RGS1), chemokine (C–C) ligand 4 (CCL4), and other immune-related
transcripts enriched in T-cell and macrophage signaling and converging in one module after weighted gene
correlation network analysis. Testing expression of this gene network in two independent cohorts of patients with
schizophrenia versus healthy controls (n= 16/50 and n= 54/45) demonstrated similar expression changes. The two
top markers RGS1 and CCL4 deﬁned a subset of 27% of patients with 97% speciﬁcity. Thus, analogous aberrant
signaling pathways can be identiﬁed by a blood test in an animal model and a corresponding schizophrenia patient
subset, suggesting that in this animal model tailored pharmacotherapies for this patient subset could be achieved.
Introduction
Despite decades of scientiﬁc efforts, schizophrenia or
other chronic mental illnesses (CMI) in clinical psychiatry
lack an objective biological diagnostic test. Diagnosis in
clinical psychiatry still relies on the subjective clinical
interview and, paradoxically, biology-based diagnostics is
used only to exclude conditions, such as trauma, drug
intoxication, or “neurological” causes.
The predicament for a biological deﬁnition of mental
illness results from the fact that all efforts for the dis-
covery of biological underpinnings start with the clinical
diagnosis that pools patients from heterogeneous biolo-
gical subsets leading to a dilution of possible size effects of
speciﬁc markers for a disease subset. This problem cannot
be solved by including larger patient numbers because
ratios of biological subsets within the clinical “umbrella”
diagnosis will remain the same.
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For example, schizophrenia is, in most cases, a chronic
disease clinically diagnosed with positive (hallucinations,
delusions, thought disorder), negative (ﬂattened affect,
lack of drive), and cognitive symptoms (working memory
and attention deﬁcits). The diversity of underlying biology
in schizophrenia patients is already mirrored by variations
in chronic impairment and biological time courses1. As
repeatedly demonstrated on the genetic level, there is
strong overlap of schizophrenia with recurrent affective
disorders2–4 arguing against the value of a purely clinical
diagnosis for investigating underlying biology. Attempts
to identify common genetic variants increasing the risk
for obtaining the clinical diagnosis schizophrenia led to
the discovery of over 108 associated loci with low loga-
rithm of odds (LOD) scores of all genes of below 18,
except MHCII with a LOD score of 30 (ref. 5). These
relatively small effect sizes could in part be due to the
“dilution of subsets” argument outlined above.
Ever since the discovery of the genetic component of
schizophrenia, it has also been recognized that a large
portion of the disease risk is actually non-genetic6. We
previously followed up the idea of subtle protein mis-
assembly or aggregation as one feature of aberrant protein
homeostasis in chronic mental illnesses(CMI)7. Since the
same proteins are detected in insoluble deposits in the
majority of sporadic cases as in the rare familial cases of
neurodegenerative diseases8, we reasoned that the products
of genes with rare mutations in familial schizophrenia
would be good candidates for protein misassembly9. In the
neurodegenerative diseases, most mutations leading to
aggregating proteins are rare mutations and, for example, in
Alzheimer’s disease, do not display common variants10. We
chose the Disrupted-in-Schizophrenia 1 (DISC1) gene that
is mutated both in a Scottish family11 and in an American
family12 and associates with schizophrenia as well as
affective disorders thus crossing current diagnostic bound-
aries. Its genetic linkage to mental illnesses has also been
reported from Finnish families13,14. When we investigated a
collection of post mortem brains from patients with schi-
zophrenia, major depression, bipolar disorder, and healthy
controls for the presence of insoluble DISC1, we identiﬁed
biochemically insoluble DISC1 in ~15% of cases with dif-
ferent clinical diagnoses9, but not healthy individuals or
controls with various neurodegenerative diseases15. DISC1
overexpression in animals or cells leads to DISC1 protein
misassembly or aggregation independent of mutations9,15,16,
and no subsequent regulation of endogenous DISC1 protein
levels has been observed16. When modeling the effects of
misassembled, full-length, non-mutant DISC1 protein on
brain functions by modestly overexpressing it as a transgene
in a rat (tgDISC1 rat, with ~11-fold overexpression com-
pared with endogenous rat Disc1)16, we observed a series of
phenotypes in independent lines with high face validity to
major mental disorders16–19. Behavioral deﬁcits were
compatible with dysregulation of dopamine home-
ostasis16,20, a major factor relevant for behavioral control,
including in schizophrenia. Neurochemical and neuroana-
tomical changes conﬁrmed the role of aberrant neurode-
velopment of the dopamine system21, as well as attention
and long-term memory deﬁcits19,20, two features high-
lighted by the Measurement and Treatment Research to
Improve Cognition in Schizophrenia (MATRICS) Initiative
for translating cognitive features of schizophrenia to animal
models22.
Accumulated research from the last decade has shown
that DISC1 is a scaffold-like protein that is participating in
several mental illness-related signaling pathways and
likely acts as a convergence point in these7,23–26. There-
fore, a subtle dysregulation of DISC1 protein functionality
as a result of its misassembly, resulting in both loss and
gain-of-function phenotypes9,15, likely impacts several
signaling pathways relevant for CMI27. Since the tgDISC1
rat demonstrates a phenotype for non-mutant DISC1
protein posttranslational alterations, i.e., protein mis-
assembly, it is a more valid model for the majority of
sporadic cases of CMI than a model with a DISC1 muta-
tion or ablation and therefore represents a valid model for
a subset of patients with sporadic schizophrenia. We
hypothesized that given the central function of the DISC1
protein in CMI-relevant signaling pathways and their
disruption in the tgDISC1 rat, we could identify biological
markers in peripheral tissues of this animal model to serve
as starting points for the discovery of similar markers in
patients, thereby revealing a shared pathophysiology. In
fact, we here successfully use this “reverse translation”
approach to translate biological markers identiﬁed in an
animal model to patients (see Fig. 1). Applying this novel
approach for mental illnesses, we here describe a dysre-
gulated network of immune-related genes, able to biolo-
gically classify a subset of 27% of schizophrenia patients
with 97% speciﬁcity, and representing speciﬁc clinical
characteristics.
Materials and methods
Subjects and classiﬁcations
The study was carried out following the rules of the
Declaration of Helsinki of 1975, revised in 2008. All
participants were fully informed about the procedures and
gave written informed consent.
Group I–HHU
Control subjects and patients diagnosed with schizo-
phrenia of group I were part of a clinical study as
described earlier28,29. Demographic information regarding
the cohort can be found in Supplementary Table 1, and
further information is available in Warbrick et al.28 and
Trossbach et al.29. The study protocol and its amend-
ments were approved by the local ethics committee
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(Medical Faculty of the Heinrich Heine University Düs-
seldorf: EudraCT-Number: 2006-006329-19).
Group II - LMU
Sample Patients were recruited at the Department for
Psychiatry and Psychotherapy, Clinic of the University of
Munich. The study protocol and its amendments were
approved by the local ethics committee (Medical Faculty
of the LMU Munich: Code 17–13; Date of Approval: 25th
of February 2013 and 25th of March 2014).
Procedure Using the Verbal Learning and Memory Test
(VLMT)30, the Digit-Span-Test (DST, subtest of
the Hamburg–Wechsler Intelligence Test)31, Digit
Symbol Substitution Test (DSST, subtest of the
Hamburg–Wechsler Intelligence Test)31, and the Trial
Making Test A and B (TMT-A, TMT-B)32, we assessed
verbal episodic memory, working memory, attention, and
cognitive ﬂexibility in Group II. The test results were
standardized (z-values) and averaged to a memory, an
attention, and a main cognition score serving as outcome
variables (for details, see Supplementary Tables 2, 3). In
addition, we assessed symptoms severity with the Positive
and Negative Syndrome Scale (PANSS)33, medication,
medical history, and demographics (Supplementary
Table 1).
Statistical analysis (Group II –LMU) We conducted all
statistical analysis at signiﬁcance level of α= 0.05 using
SPSS 24 (IBM, Ehningen, Germany) for Windows. First,
we compared cognitive performance between patients
with and without marker combination (for explanation,
see the Results section), using univariate ANOVAs. In
case of violation of the assumption of homogeneity of
variances, we applied Welch’s ANOVA. Then, we tested if
and how gene expressions of RGS1, CCL4, DISC1, as well
as the RGS1+CCL4 combination are associated with
cognitive functioning with Kendall’s tau correlation
analysis. Demographic and clinical differences between
both patient groups were carried out using ANOVAs. The
results are presented without correction for multiple
testing.
Fig. 1 The reverse translation approach to biomarker discovery. The heterogeneous group of mental illness patients lacks a clear biology-based
clinical categorization which impedes attempts for the discovery of objective biomarkers so far. By deﬁning biological subgroups based on human
neuropathobiochemistry, in our case misassembled DISC1 protein in post mortem brain9, we were able to design a transgenic rat model for this
speciﬁc subset16 that demonstrated aberrant signaling networks of key pathways relevant for schizophrenia27. Utilizing this animal model as a
prototype for subtly deranged signaling networks essential for behavioral control, peripheral markers were identiﬁed in this animal model which, in a
so-called “reverse translational approach”, were translated back into schizophrenia patient cohorts, coming full circle for deﬁning subsets of mental
illness patients
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Animals
Animal experiments were executed in conformity with
the German Animal Protection Law and were authorized
by local authorities (LANUV NRW, Recklinghausen,
Germany). Blood extraction, splenocyte extraction, and
preparation of PBMCs were performed with transgenic
Sprague Dawley rats overexpressing full-length, non-
mutant DISC1 (tgDISC1 rat, TG, see ref. 16 for full
description) and non-transgenic littermates (LM). All rats
were males and 8–9 months old. TgDISC1 and control
rats were bred at the ZETT, Heinrich Heine University
Düsseldorf, Germany. Animals were housed three animals
per cage under standard laboratory conditions with lights
on from 7 a.m. to 7 p.m. and with water and food provided
ad libitum.
Preparation of rat peripheral blood mononuclear cells
(PBMCs) from blood
Anaesthetized rats underwent a heart puncture to har-
vest a minimum of 8 mL of blood with 10mM EDTA as
an anti-coagulant. Rat PBMCs were prepared with Ficoll-
Paque Premium 1.084 solution (GE Healthcare, Little
Chalfont, UK) according to the manufacturer’s instruc-
tions. Preparation of human PBMCs was performed with
Ficoll-Paque Plus as described earlier29. All lymphocyte
samples were snap-frozen in liquid nitrogen and stored at
−80 °C until further processing.
Preparation of rat splenocytes
The spleen was dissected out of rats (n= 5 TG and LM)
and forced through a 70 µm cell strainer to get a single-
cell suspension. The cell strainer was washed afterwards
twice with PBS+ 2% FCS.
Antibody staining for ﬂow cytometry
Rat blood and splenocytes (n= 5 each for TG and LM)
were stained for 30min at 4 °C with antibodies according
to the manufacturer’s recommendations. Following anti-
bodies were used: anti-rat CD3, FITC, clone 1F4, BioLe-
gend; anti-rat CD4, PE-Cy7, clone W3/25, BioLegend; anti-
rat CD8, Pe, clone G28, BioLegend; anti-rat CD45, BV510,
clone OX-1, BD Biosciences; anti-rat CD45RA, PerCP-
Cy5.5, clone OX-33, BioLegend; anti-rat CD161a, BV421,
clone 10/78, BD Biosciences. After staining, cells were
washed twice and erythrocytes were lysed using VersaLy-
seTM Lysing Solution (Beckman Coulter, Krefeld, Ger-
many) according to the manufacturer’s recommendations.
Afterward, cells were acquired with a GalliosTM (Beckman
Coulter) ﬂow cytometer and analyzed with FlowJo analysis
software v10.4.1 (Tree Star, Inc., Ashland, USA).
Generation of single-cell libraries and sequencing
Human PBMCs intended for single-cell sequencing were
isolated using Lymphoprep (STEMCELL Technologies,
Vancouver, Canada) according to the manufacturer’s
instructions from a single healthy donor. In total,
150,000 single cells were processed with the Drop-Seq
technique as previously described34 to capture about 3,500
cells. Library Preparation was carried out with the Nextera
XT Kit (Illumina, San Diego, USA) according to the
manufacturer’s instructions. Sequencing was performed
on a local Illumina Nextseq 500 using the High-Out 75
cycle kit with a 20–8–0–63 read setup, aiming at
40,000–50,000 reads/cells.
Single-cell RNA-sequencing data analysis
Raw sequencing data were preprocessed by the Drop-Seq
tools v1.12 pipeline. A single cell gene expression data set
derived from one healthy donor for 8,000 PBMCs was down-
loaded from ×10 Genomics (support.10xgenomics.com).
Subsequent analysis was carried out with the R-package
Seurat v2.135, using R v3.4.3 and RStudio v1.1.383. In a ﬁrst
step, low-quality cells and cell duplets were removed from
the data set. The data were then normalized and variable
genes were identiﬁed by calculating the average expression
and dispersion for each gene. Linear dimensional reduction
was done using Principal Component Analysis (PCA) using
the identiﬁed variable genes as input. Statistically signiﬁcant
Principal Components (PCs) were identiﬁed by a combina-
tion of a JackStraw signiﬁcance test and plotting standard
deviations of the PCs. Cell clustering was based on a graph-
based clustering approach, employing K-nearest neighbor
(KNN), and then visualized by t-distributed stochastic
neighbor embedding (t-SNE). Differentially expressed genes
were identiﬁed by a tobit-censoring model for zero inﬂated
data35.
Preparation of RNA and cDNA
RNA of rat and human PBMCs was prepared utilizing
the RNeasy Mini Kit according to manufacturer’s guide-
lines. Residual genomic DNA was digested on column by
the RNase-free DNaseI Set (both Qiagen, Hilden, Ger-
many). RNA from PBMCs collection was diluted to a
concentration of 100 ng/µL and 1 µg was used as input for
the production of cDNA with the RevertAid Minus H
First Strand Synthesis Kit in a total of 20 µL utilizing the
random hexamer primers provided by the kit (Thermo
Fisher Scientiﬁc, Waltham, MA, USA). The resulting
cDNA was diluted 1:50, 1:25, or 1:10 dependent on the
PCR results as indicated in Supplementary Table 4, and
5 µL were used as template input. All analyses were per-
formed blind to diagnosis.
Gene expression proﬁling
The total RNA preparations were checked for RNA
integrity by Agilent 2100 Bioanalyzer quality control. All
samples in this study showed high-quality RNA integrity
numbers (RIN >9). RNA was further analyzed by
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photometric Nanodrop measurement and quantiﬁed by
ﬂuorometric Qubit RNA assays (Life Technologies,
Waltham, USA).
Synthesis of biotin-labeled cDNA was performed on ten
replicates of each experimental group (DISC1 transgenic
(TG) rats and littermate (LM) controls, respectively),
according to the manufacturer's protocol (WT Plus
Reagent Kit; Affymetrix Inc, Waltham, USA). Brieﬂy,
100 ng of the total RNA were converted to cDNA. After
ampliﬁcation by in vitro transcription and second cycle
synthesis, cDNA was fragmented and biotin labeled by
terminal transferase. Finally, end-labeled cDNA was
hybridized to Affymetrix Rat Gene 2.0 ST Gene Expres-
sion Microarrays for 16 h at 45 °C, stained by strepatavi-
din/phycoerythrin conjugate, and scanned as described in
the manufacturer's protocol.
Three samples (2x TG, 1x LM) did not pass hybridiza-
tion quality control, two additional samples (3x TG, 2x
LM) had to be excluded from further analyses because of a
non-transgene-related malformation diagnosed after ter-
mination, leading to a ﬁnal n= 7 for LM and n= 5 for TG.
The data analyses on 12 Affymetrix CEL ﬁles were
conducted with GeneSpring GX software (Vers. 12.5;
Agilent Technologies, Santa Clara, USA). Probes within
each probeset were summarized by GeneSprings’
ExonRMA16 algorithm after quantile normalization of
probe-level signal intensities across all samples to reduce
inter-array variability. Input data pre-processing was
concluded by baseline transformation to the median of all
samples.
To further improve signal-to-noise ratio, a given pro-
beset had to be expressed above background (i.e. ﬂuor-
escence signal of a probeset was detected within the 20th
and 100th percentiles of the raw signal distribution of a
given array) in all replicates in at least one of two, or both
conditions to be subsequently analyzed in pairwise
comparison.
Differential gene expression was statistically determined
by moderated T test36. The signiﬁcance threshold was set
to p= 0.01. No correction for multiple testing was applied.
Coexpression network WGCNA analysis
Gene coexpression network analysis
The normalized Affymetrix data from the differential
gene-expression proﬁling was used to build a coexpres-
sion network using the “WGCNA” R package37. The data
set contained 29,489 expression values from 12 samples.
Samples encompass the ﬁve DISC1 transgenic (TG) rats
and seven littermate (LM) controls. Following the steps
described in Langfelder, P. and Horvath37, we ﬁrst build
an adjacency matrix Am,n based on Pearson’s pairwise
correlation between gene (m and n) raised to a power β
(soft thresholding) Am,n= |cor(m,n)|^β in order to
emphasize high correlations at the expense of low
correlations. The soft thresholding parameter (β= 6) was
deﬁned using the R function “pickSoftThreshold” from
the WGCNA package. Using this approach, we construct
an unsigned correlation network considering absolute
correlation values. Therefore, we are able to identify
highly co-expressed genes and test only for differences
between TG and LM rats. In a next step, the adjacency
data were used to build the topologic overlap matrix
(TOM), which is a measure of connectivity of a particular
gene as the sum of its adjacency with all other genes from
the network. The corresponding dissimilarity, which is
used as a proxy for distance between a pair of genes, was
therefore deﬁned as 1-TOM.
Identiﬁcation of signiﬁcant modules
To classify genes with similar expression pattern into
gene modules, hierarchical clustering was performed
using the TOM dissimilarity as distance and average
linkage as clustering method. Distance between modules
was inferred from the dissimilarity between module
eigengenes (MEs), this is the ﬁrst principal component of
a given module. Modules having short distances to each
other were merged together resulting in a total of 104
modules. In order to identify modules and genes with
expression level related to clinical traits (TG or LM),
Pearson’s correlation between module eigengenes (MEs),
gene expression, and trait information was performed.
Signiﬁcance was calculated using the R function “corP-
valueStudent” from the WGCNA package. Ten out of 104
modules have a p-value lower 0.05, and were considered
signiﬁcant. To be very strict in our analysis, we choose the
module (hotpink4) with highest correlation (ρ= 0.7429)
and lowest p-value (0.0056), respectively to the trait
information for further evaluation.
Identiﬁcation of hub genes
Hub genes are highly interconnected genes in a module,
and can be considered to be functionally central. In our
study, hub genes were deﬁned by absolute values of
Pearson’s correlation of module membership > 0.8 and
trait information, gene trait signiﬁcance and intra-module
connectivity >0.5. Due to the fact that we used an
unsigned network, in a second step the module members
were separated into two subsets according to their cor-
relation sign, which represents (i) the reduced expression
level in TG compared with LM (negative correlation) and
(ii) elevated level of expression in TG compared with LM
(positive correlation). The top 10 hub genes for each
subset sorted by mean correlation, intra-module con-
nectivity, and module.
Stress centrality
The subset with reduced expression level in TG samples
compared with LM was used for further centrality
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analysis. To ﬁnd out which node in the module is most
“important” or possesses high “control” to the network,
we measured the stress centrality for each node using
Cytoscape38 NetworkAnalyzer module. Stress centrality,
introduced by Shimbel39 is based on enumeration of these
shortest paths. The goal of deﬁning this measure is to ﬁnd
the amount of “work” done by each node in the network.
In a network representation, the nodes correspond to the
genes and edges to the transformed Pearson’s correlation
from the adjacency matrix with values >0.2. The node size
is proportional to the importance (stress centrality) of the
node in the network with Rgs1 having the highest
number (424).
Quantitative expression analysis
For the veriﬁcation of differential expression, target
primers were tested by PCR using the HotStarTaq (Qia-
gen, Hilden, Germany). Effective primers were used for
quantitative real-time PCR (qPCR) with the StepOnePlus
Real-Time PCR System (Applied Biosystems, Carlsbad,
CA, USA) and the Platinum SYBR Green qPCR
SuperMix-UDG (Invitrogen, Carlsbad, CA, USA) in
MicroAMP Fast Optical 96-Well Reaction Plates (Applied
Biosystems, Carlsbad, CA, USA). Depending on the target,
5% Factor Q solution (Qiagen, Hilden, Germany) was
added to the mix. A detailed list of primers used and
additional information, as well as the n for every single
analysis can be found in Supplementary Table 4. QPCR
conditions: 10 min at 95 °C, 40 cycles of 15 s at 95 °C, and
60 °C for 1 min. The resulting data were processed with
the corresponding StepOne Software v2.3 (Thermo Fisher
Scientiﬁc, Waltham, MA, USA). The expression of the
respective target was normalized to the expression level of
the housekeeping gene Actin (rat) or ARF1 (human), as
well as against a rat or human PBMC control cDNA per
plate to minimize variances between runs.
SMRI (Stanley Medical Research Institute) array collection
of brain RNA
The array collection of puriﬁed RNA from cohorts of
patients with schizophrenia, bipolar disorder, and healthy
controls from the BA9 region was obtained from the Stanley
Medical Research Institute (www.stanleyresearch.org). Area
BA9 was used due to availability of the RNA samples and is a
location of interest for schizophrenia or bipolar
disorders40,41. A detailed list of sample demographics and
tissue information can be found online (http://www.
stanleyresearch.org/brain-research/array-collection/). A rev-
ised table, summarizing the patient and tissue information of
cases shown, can be found in Supplementary Table 5.
CDNA synthesis and qPCR was performed as described in
the section “Quantitative expression analysis”, with the only
difference that 5 µL of 1:5 diluted cDNA was used as input.
The integrity of the RNA was tested using the Fragment
Analyzer (Advanced Analytical Technologies, Thermo
Fisher, USA). Only RNA with an integrity score (RNA
Quality Number; RQN) >8 was used for further analysis. For
normalization, the housekeeping gene ARF1 was used. After
the blind analysis of the qPCR, all samples with a Ct value
>29 for RGS1 were considered as showing no expression of
RGS1 in the brain.
Statistics
Statistical analyses were performed with the IBM SPSS
Statistic program (IBM, Ehningen, Germany) or Graph-
Pad Prism Version 6 (GraphPad Software Inc., San Diego,
CA, USA). All data sets were tested for normal distribu-
tion, and appropriate parametric or non-parametric tests
were chosen. Two datasets were tested by two-tailed
Student’s t test or Mann–Whitney U test, respectively, if
not stated otherwise. Correlations were analyzed by
Spearman’s ranked test. For association between catego-
rical variables, chi-square analyses were performed.
Results
A unique signature of dysregulated genes in peripheral
blood mononuclear cells (PBMCs) of the tgDISC1 rat
In order to identify peripherally accessible, differentially
expressed genes in our rat model for sporadic chronic
mental illnesses, the tgDISC1 rat, we performed a
microarray analysis of puriﬁed PBMCs from blood of
tgDISC1, as well as wild-type littermate control rats. We
identiﬁed various changes in gene expression, mostly
downregulation, in PBMCs of the tgDISC1 rat (Table 1,
see Supplementary Table 6 for an extended number). The
top differentially expressed genes were regulator of G-
protein signaling 1 (Rgs1) and chemokine (C–C motif)
ligand 4 (Ccl4). Quantitative PCR of the target genes
conﬁrmed the expression changes in the transgenic rats
(Supplementary Fig. S1). The top hits were reported to be
expressed mainly in T cells and NK cells (Fig. 2a), and an
analysis of the extended list of transcripts with at least a
fold change of 1.2 as cutoff showed enrichment of genes
expressed in activated macrophages, CD8+ myeloid den-
dritic cells, granulocytes, NK cells, and microglia (Fig. 2b).
The gene ontology and ingenuity pathway analysis
indicated enrichment of signaling pathways important for
toll-like receptor signaling, T-cell activation and pro-
liferation, communication between innate and adaptive
immune response, and others (Table 2). In order to
investigate which of our deregulated transcripts were part
of coexpression networks and whether these networks
were dysregulated in the tgDISC1 model compared with
littermate controls, a weighted gene correlation network
analysis WGCNA37 was performed (Supplementary Fig.
S2). In this procedure, genes with similar expression
patterns were classiﬁed into a total of 104 gene modules of
which 10 were signiﬁcantly altered in the tgDISC1 rat,
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with the module “hotpink4” displaying highest sig-
niﬁcance. Further analysis of the genes that are highly
interconnected within that particular module by the
Cytoscape NetworkAnalyzer indicated the microarray top
hits Rgs1 and Ccl4 as functionally central hubs within that
same module (Fig. 2c).
In order to analyze whether tgDISC1 rats exhibit an
altered distribution of immune cell types, ﬂow-cytometric
phenotyping was performed, showing no signiﬁcant dif-
ferences between genotypes (Supplementary Fig. S3 for
blood; S4 for splenocytes), although there was a strong
trend toward increased T-cell number in tgDISC1 rats
and signiﬁcantly increased Cd3g expression, a pan T-cell
marker, in PBMCs of the tgDISC1 rat (Supplementary Fig.
S1I). Nevertheless, Cd3g level did not correlate with either
Rgs1 or Ccl4 (Supplementary Fig. S1K) and an analysis of
covariance conﬁrmed that Cd3g is not a co-variate of Rgs1
[F(1,12)= 0.981, p= 0.342] or Ccl4 expression F(1,11)=
0.036, p= 0.853] in between-group analyses, which hints
toward the fact that the reduction in transcript levels is
due to a net reduced expression and not a reduction in the
expressing cell-type number.
Table 1 Top 20 genes differentially expressed in PBMCs of tgDISC1 rats compared with littermate controls
Entry name Gene symbol [rat] Gene symbol
[human]
Protein name TG versus LM qPCR
performed
Change FC P rat human
1 RGS1_RAT Rgs1 RGS1 Regulator of G-protein signaling 1 ↓ 2.03 0.0062 Y Y
2 CCL4_RAT Ccl4 CCL4 Chemokine (C–C motif) ligand 4 ↓ 1.67 0.0001 Y Y
3 D4A8L8_RAT Fpr2|Fpr2l FPR2 Formyl peptide receptor 2 | Formyl peptide
receptor 2-like
↓ 1.65 0.0053 n.d. Y
4 CO3_RAT C3 C3 Complement component 3 ↓ 1.63 0.0037 Y Y
5 Q9WVL9_RAT Nkg7 NKG7 Natural killer cell group 7 ↓ 1.60 0.0004 Y Y
6 F1LRH7_RAT Il12rb2 IL12RB2 Interleukin 12 receptor, beta 2 ↓ 1.59 0.0095 Y Y
7 ILEUA_RAT Serpinb1a SERPINB1 Serine proteinase inhibitor, clade B,
member 1a
↓ 1.52 0.0071 Y Y
8 Q5MPU9_RAT Ly49si3 – Immunoreceptor Ly49si2 ↓ 1.51 0.0060 n.d. n.d.
9 Q5M7T7_RAT Pla2g7 PLA2G7 Phospholipase A2, group VII ↓ 1.48 0.0056 n.d. n.d.
10 H2A2A_RAT LOC690131|
Hist2h2aa3
HIST2H2AA3 Similar to H2A histone family, member O |
Histone cluster 2, H2aa3
↓ 1.47 0.0002 n.d. n.d.
11 Q66HN6_RAT Slc27a2 SLC27A2 Solute carrier family 27 (fatty acid transporter),
member 2
↓ 1.46 0.0089 Y Y
12 Q561K3_RAT Il13ra1 IL13RA1 Interleukin 13 receptor, alpha 1 ↓ 1.45 0.0074 Y Y
13 CP4F3_RAT Cyp4f18 CYP4F2 Cytochrome P450, family 4, subfamily f,
polypeptide 18
↓ 1.44 0.0038 n.d. n.d.
14 RL10_RAT Rpl10 RPL10 Ribosomal protein L10 ↓ 1.41 0.0059 n.d. n.d.
15 D3ZPB4_RAT Olr428 OR1L6 Olfactory receptor 428 ↑ 1.41 0.0092 n.d. n.d.
16 IFNG_RAT Ifng IFNG Interferon gamma ↓ 1.38 0.0014 Y Y
17 D1MF50_RAT RGD
1561778
CD300C Similar to dendritic cell-derived
immunoglobulin-like receptor 1
↓ 1.38 0.0055 n.d. n.d.
18 F1LYV1_RAT Scimp SCIMP SLP adaptor and CSK interacting membrane
protein
↓ 1.37 0.0018 n.d. n.d.
19 TSN31_RAT Tspan31 TSPAN31 Tetraspanin 31 ↓ 1.36 0.0041 n.d. n.d.
20 D4AC93_RAT Tmem223 TMEM223 Transmembrane protein 223 ↓ 1.35 0.0050 n.d. n.d.
Arrow down, reduced expression in tgDISC1 rats, arrow up, increased expression in tgDISC1 rats. FC fold change, qPCR quantitative real-time PCR, n.d. not determined,
Y qPCR performed (yes), LM non-transgenic littermate control, TG tgDISC1 rat
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Taken together, these results indicate that the tgDISC1
rat displays a speciﬁc dysregulated network of immune-
related genes.
Genes differentially expressed in the tgDISC1 rat are
similarly modulated in patients with schizophrenia
We next hypothesized that the PBMC gene expression
changes in the tgDISC1 rat, as a model for subtly deranged
DISC1-related signaling pathways, may reveal a similar
signature of gene-expression changes in a subset of
patients with schizophrenia where, potentially, signaling
pathways of the extended DISC1 network are aberrant.
We therefore ﬁrst quantiﬁed the expression of the human
orthologues corresponding to the top candidate genes
deregulated in the tgDISC1 rat (listed in Table 1) by qPCR
in a limited cohort of patients (group I26,29, for demo-
graphic information, see Supplementary Table 1) diag-
nosed with schizophrenia according to DSMIV/SCID and
matched controls. In concurrence with this hypothesis, the
top candidates RGS1, CCL4, and others were decreased
and showed a similar pattern of regulation as observed in
the tgDISC1 rat (Table 4; Supplementary Fig. S5A–F).
Fig. 2 Assignment of top different transcripts of the tgDISC1 rat versus littermate control to peripheral blood mononuclear cell (PBMC)
subtypes. a Top markers are mainly found in T cells and NK cells. Red: strong effects, light red: medium effects, white: weak effects. b A cell-type
enrichment analysis (Cten; http://www.inﬂuenza-x.org/~jshoemaker/cten/)63 of the extended differential expression table (Supplementary Table 6)
identiﬁed enrichment of differentially regulated transcripts in myeloid CD8+ dendritic cells, macrophages, granulocytes, NK cells, and microglia. See
red line in inner circle for 1–10 fold enrichment. Red: strong association, light red: medium association, black: weak association. c Cytoscape
illustration of the coexpression network with reduced expression levels in TG from the highly signiﬁcantly deregulated “hotpink4” module after
WGCNA. Nodes correspond to genes and edges connect co-expressed nodes with an adjacency value >0.2. Edge thickness corresponds to adjacency
value. The node size is proportional to the stress centrality (importance) of the node, color represents the degree (number of edges) connectivity of
the node from white (low) to dark orange (high)
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To corroborate the differential expression of these
markers, we obtained samples from an independent and
larger cohort of well-characterized schizophrenia cases
and controls (group II, for demographic information, see
Supplementary Table 1) that were tested blind with regard
to diagnosis. Again, the top candidates RGS1, CCL4, and
others were signiﬁcantly decreased (Supplementary Figs.
S5A–F, S6A–H). A summary of qPCR results of all targets
tested in the tgDISC1 rat and the two independent human
cohorts is provided in Table 3. We also tested whether
RGS1, which is expressed by microglia, is differentially
expressed in the brain samples of mental illness patients,
but could not detect signiﬁcant differences in patients and
controls (Supplementary Table 5). CCL4 was not inves-
tigated, as it is not expressed in the brain.
Our ﬁndings regarding transcript levels were based on
frozen human PBMCs that derive from a complex mix-
ture of cell types. We therefore aimed to understand
which cell type caused differential expression of the can-
didate marker genes in the absence of available ﬂow-
cytometry data for these same patients. We investigated
the cell-type-speciﬁc expression of the marker genes by
performing microﬂuidics-based single-cell RNA sequen-
cing34 on ~3,000 human healthy donor-derived PBMCs.
We also queried a published data set of ~8000 human
PBMCs generated using a similar single-cell RNA-
sequencing technique42 to validate the cell-type expres-
sion pattern in an independent dataset, as both derive
from one donor. This combined approach conﬁrmed the
expression of the top genes in speciﬁc subpopulations of
PBMCs (Supplementary Figs. S7, S8). We also used this
data set to identify the most abundant cellular source of
the marker genes. We found most abundant expression of
the marker CCL4 in CD8+ T cells and natural killer (NK)
cells and RGS1 with a predominance in CD4+ T cells even
though present at low level in most cells (Fig. 2a; Sup-
plementary Fig. S7A–D). This indicated that reduced
expression of CCL4 could be due to its reduced expres-
sion by CD8+ T cells/NK cells, reduced abundance of
CD8+ T cells/NK cell numbers in patients, or both.
Similarly, RGS1 expression could correlate with cell
abundance or expression in CD4+ T cells.
To further address this issue, we performed qPCR for
major markers of monocytes, T and NK cells (CD14, CD4,
CD8, NKp46, respectively; Supplementary Fig. S5G–J), in
which the top targets were most abundantly expressed in
group II. Even though NK cell marker NKp46 was sig-
niﬁcantly reduced in SCZ patients of group II (Supple-
mentary Fig. S5H), an analysis of covariance (ANCOVA)
for the cell-type markers as co-variate was negative for
RGS1 (CD4 F(1, 81)= 0.301, p= 0.585; CD8 F(1,82)=
0.146, p= 0.703; NKp46 F(1, 72)= 0.477, p= 0.492; CD14
Table 2 Bioinformatic analysis of the microarray data (Supplementary Table 6) by Gene Ontology/Panther (top panel)
or ingenuity pathway analysis (bottom panel)
Gene Ontology/Panther 13.1. Raw
Name P FDR
Positive regulation of toll-like receptor signaling pathway 1.14E-04 3.03E-02
Positive regulation of reactive oxygen species biosynthetic process 1.30E-04 3.23E-02
Cytokine production involved in immune response 2.08E-04 4.53E-02
Regulation of CD4-positive, alpha/beta T-cell activation 6.38E-05 2.00E-02
Positive regulation of cytokine production 1.16E-08 6.05E-05
Regulation of lymphocte proliferation 4.05E-05 1.47E-02
Positive regulation of ERK1 and ERK2 cascade 2.39E-04 4.80E-02
Ingenuity pathway analysis/top canonical pathways
Name P Overlap
Communication between innate and adaptive immune cells 2.34E-05 4.3% 4/94
Role of hypercytokinemia in the pathogenesis of inﬂuenza 6.15E-05 7.0% 3/43
Altered T-cell and B-cell signaling in rheumatoid arthritis 5.52E-04 3.3% 3/90
Differential regulation of cytokine production in intestinal epithelial
cells by IL17A and IL17F
7.65E-04 8.7% 2/23
Natural killer cell signaling 1.33E-03 2.5% 3/122
FDR false discovery rate
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F(1, 75)= 681.136, p= 0.583). For CCL4, solely NKp46
was found to be a co-variate (CD4 F(1, 79)= 0.025, p=
0.875; CD8 F(1, 80)= 1.486, p= 0.226; NKp46 F(1, 71)=
36.764, p < 0.001; CD14 F(1, 73)= 1.454, p= 0.232) and
the expression of these two genes correlated (Fig. 3a),
arguing that the expression change of CCL4 is also par-
tially caused by a change in NKp46-positive cells that
mainly comprises the NK cell population. T cells, how-
ever, are the most abundant cell type in PBMCs (about
50%), and NK cells comprise only around 10%43 (Fig. 2a),
which makes the decrease of transcript levels likely due to
their decreased expression in T cells. This result also leads
to the conclusion that one single marker is not sufﬁcient
to serve as a biomarker but that expression changes of
several genes, preferably from a single module in the
identiﬁed dysregulated network (see Fig. 2c) should be
taken into account (see also Discussion section).
We also analyzed expression of several other genes to
further delineate the nature of the dysregulation of the net-
work of immune-related genes in patients, potentially par-
alleling the one discovered in the tgDISC1 rat. In human
PBMCs, DISC1 itself was overall expressed at low levels in
blood cells with highest expression in CD14+monocytes and
memory T cells (Supplementary Fig. S7E, F). In our data, we
found cell-type-speciﬁc expression patterns of the prion
protein (PrP) comparable with that of DISC1 (Supplemen-
tary Fig. S7G–H), but much higher, as expected. This is a
relevant control because DISC1 expression in the tgDISC1
rat is driven by the PrP promoter16. Furthermore, we also
analyzed expression of interleukin (IL)-1β that has previously
been reported as elevated in full blood samples of schizo-
phrenia patients44, but IL-1β transcript levels in PBMCs
measured by qPCR were unchanged (Supplementary Fig.
S6I). Gene-expression proﬁles of the other targets tested in
PBMCs subclasses can be found in Supplementary Fig. S8.
A matrix of coregulated genes indicates that a speciﬁc,
minimal combination of two markers deﬁnes a subset of
~25% of patients with schizophrenia with 97% speciﬁcity
The top markers identiﬁed in the tgDISC1 rat formed a
highly expression-correlated network of genes in human
PBMCs (Fig. 3a; Supplementary Fig. S9). Whereas many
correlations in the regulation of expression levels were
concordant in both, healthy controls and schizophrenia
patients (dark blue in Fig. 3a), indicating a functionally
maintained network of gene regulation, other correlation
pairs of coexpression were disturbed, for example, when
either coregulation existing in healthy controls was
abolished in patients (light blue), or newly emerged in the
disease condition (red). Thus, the markers identiﬁed in
the tgDISC1 rat PBMCs are evidence of a profoundly
disturbed gene-expression network also mirrored in
PBMCs of patients with schizophrenia.
These results suggested that a particular combination of
complementary markers characteristic for this dysregu-
lated network could represent a signature for a biologi-
cally deﬁned subset of schizophrenia. Therefore,
measuring a selection of several markers from Table 1,
Supplementary Table 6, or combinations thereof, would
lead to a panel of markers similarly changed in the
tgDISC1 rat and a schizophrenia subset, as evidence of
aberrant signaling of a pathway with DISC1 protein
involvement. Since investigating such a complex panel
potentially poses problems for clinical practice, we set out
to more speciﬁcally deﬁne a minimal marker combination
discriminating a subset of patients with high speciﬁcity.
We chose the two top markers RGS1 and CCL4 since they
Table 3 Overview table summarizing the different
targets tested in both rat and human cohorts
Rat Human qPCR
Target Microarray qPCR Group I Group II
RGS1 ↓ decrease ↓ decrease ↓ decrease ↓ decrease
CCL4 ↓ decrease ↓ decrease ↓ decrease ↓ decrease
NKG7 ↓ decrease n.s. n.s. ↓ decrease
C3 ↓ decrease ↓ decrease ↓ decrease n.s.
IL12RB2 ↓ decrease n.s. n.s. ↓ decrease
DISC1 – n.d. n.s. n.s.
IFNG ↓ decrease ↓ decrease n.s. n.s.
IL13RA1 ↓ decrease n.s. n.s. n.s.
SLC27A2 ↓ decrease n.s. n.s. n.s.
CCR5 ↓ decrease n.d. n.s. n.s.
SERPINB1 ↓ decrease n.d. n.d. n.s.
KMO ↓ decrease n.d. n.d. ↑ increase
FPR2 ↓ decrease n.d. n.d. ↑ increase
JAK2 n.d. n.d. n.d. n.s.
IL1B – n.d. n.d. n.s.
CD14 – n.d. n.d. ↑ increase
NKp46 – n.d. n.d. ↓ decrease
CD4 – n.d. n.d. n.s.
CD8B – n.d. n.d. n.s.
CD3g – ↑ increase n.d. n.d.
CD11b – n.s. n.d. n.d.
Arrow down marks a downregulation, arrow up an upregulation of the single
targets in tgDISC1 rats or SCZ patients compared to the respective controls.
Human samples are split for the two independent cohorts analyzed (group I
and II)
n.s. no signiﬁcant difference, n.d. not determined
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were both decreased in the tgDISC1 rat and the two
human cohorts (Table 3), appear both as hub genes in the
WGCNA analysis (Fig. 2c), and do not directly correlate
in the correlation matrix of human PBMC gene expres-
sion (Fig. 3a), indicating that they could complement
each other.
When an arbitrary threshold for the combined RGS1
and CCL4 expression level analysis was set to be below
50% of the mean level of RGS1 and CCL4 expressed in
healthy controls, the combination of both genes resulted
in a speciﬁcity of detection of 97% in identifying the
PBMC samples of schizophrenia patients correctly (Fig.
3b). The sensitivity was about 27% meaning that the test is
valid for a subset of clinically deﬁned patients that com-
prises roughly a fourth of the clinically deﬁned schizo-
phrenia cases. RGS1 and CCL4 analyzed on their own also
had a high speciﬁcity of detection alone but their com-
bination may have diagnostic advantages (see the Dis-
cussion section).
Validation of the RGS1/CCL4 marker combination by a
correlation with clinical and cognitive endophenotypes
To further investigate the signiﬁcance of the identiﬁed
markers, PBMC gene-expression levels were analyzed
with regard to clinical and cognitive variables obtained
from the schizophrenia patients of group II. Gene-
expression analysis revealed the positive marker combi-
nation (RGS1/CCL4) as deﬁned in Fig. 3b in 13 patients
(n= 13). Group comparisons between this marker-
deﬁned subset and the other, “marker-negative” SCZ
patients (n= 37) showed no signiﬁcant differences in their
medical history, years of education, and cross-sectional
chlorpromazine equivalents at the day of blood drawing
(Table 4). The absence of a statistically signiﬁcant corre-
lation between cross-sectional chlorpromazine equiva-
lents, i.e., the dosage of neuroleptic medication
administered at the time of blood drawing, argues against
an inﬂuence of medication on the levels of RGS1 and
CCL4. Patients in the marker-negative group showed
Fig. 3 Non-correlating expression markers yield highest diagnostic speciﬁcity for schizophrenia patients. a The correlation matrix depicts
present or absent co-regulated gene expression of the top hits in PBMCs derived from human schizophrenia patients and healthy controls. Individual
expression levels were correlated using Spearman’s ranked test (group II).+ stands for a positive, − for a negative correlation between target
expression. Dark blue color indicates correlations that appear in both, SCZ and CTRL subjects; light blue color marks correlations seen only in CTRL
subjects, i.e., that were lost in SCZ cases; correlations exclusively appearing in SCZ patients are depicted in red color, color-coding for physiological
(light to dark blue) to more pathological (red) relations. All correlation coefﬁcients, P-values and speciﬁc n can be found in Supplementary Fig. S9. b
Speciﬁcity and sensitivity of potential biomarkers RGS1 and CCL4 in the detection of schizophrenia (SCZ) patients. Only cases that showed a target
expression lower that 50% of the mean of control (CTRL) cases were counted as detected. By this analysis, information concerning sensitivity and
speciﬁcity of the targets RGS1 and CCL4 could be gathered. By utilizing RGS1 levels alone, a subgroup of 31% of the SCZ cases could be detected,
with a false positively detecting 12% of CTRL subjects. CCL4 analyzed in that manner identiﬁed a subgroup of 39% of SCZ patients with a speciﬁcity of
95% for detection of SCZ patients. A combination of both biomarkers led to a speciﬁcity of 97% and a sensitivity of 27%. CTRL control subjects, SCZ
schizophrenia patients
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slightly more general symptoms (p= 0.035) as measured
by the Positive and Negative Syndrome Scale (PANSS;
Table 4). Comparison of means (Supplementary Table 2)
revealed that the marker combination of RGS1+CCL4
but not RGS1, CCL4, or DISC1 expression alone associated
with better performance in the Digit Symbol Substitution
Test (DSST, p= 0.027) that comprises testing for memory
and attention. However, the lacking for multiple testing
and the inequality of the sample sizes are potential caveats
of this result. Further data regarding cognition and marker
correlations can be found in Supplementary Table 3.
Pharmacological guidelines in Germany recommend usage
of clozapine after unsuccessful therapeutic administration of
at least two non-clozapine antipsychotics of different che-
mical classes45. Patients who receive clozapine are therefore
likely non-responders to typical dopamine-2
receptor–antagonist pharmacotherapeutic treatment. In
this study, patients with the positive marker combination
showed a later age of onset of disease and higher proneness
to receive clozapine treatment (Table 4; 8/13 marker-
positive patients clozapine-treated vs. 5/37 marker-negative,
non-clozapine-treated schizophrenia patients), albeit due to
the small number of cases only at the level of a statistical
trend at borderline signiﬁcance (p= 0.053), suggesting that,
potentially, the marker combination could relate to a bio-
logical subset less susceptible to typical neuroleptic phar-
macotherapy (Table 4).
Discussion
In this study, we identiﬁed a subset of schizophrenia
patients (27%) characterized by a unique dysregulation of
a network of immune-related genes, a delayed age of
disease onset, as well as lighter positive, negative, and
cognitive symptoms. The identiﬁcation of this biologically
deﬁnable schizophrenia subset was achieved by reverse
translating (Fig. 1) PBMC transcripts identiﬁed as
Table 4 Demographic and clinical characteristics of the marker-positive subgroup of cohort II
No marker combination
(n= 37)
Marker combination
(n= 13)
F(df1, df2) P
M (SD) M (SD)
Age 32.24 (11.13) 40 (11.19) 4.66 (1, 48) 0.036*
Duration of illness 8.55 (9.04) 9.54 (8.33) 0.12 (1, 48) 0.732
Hospitalizations 4.03 (3.33) 3.15 (1.57) 1.54 (1, 43.31) 0.222
PANSS total 61.67 (17.50) 54.92 (12.44) 1.62 (1, 47) 0.209
PANSS positive 14.03 (5.59) 11.54 (3.57) 2.23 (1, 47) 0.142
PANSS negative 16.75 (5.12) 16.69 (6.58) <0.01 (1, 47) 0.125
PANSS general 30.89 (9.31) 26.69 (4.11) 4.75 (1, 44.86) 0.035*
No marker combination
(n= 37)
Marker combination
(n= 13)
Mdn Mdn U P
CPZ 467.86 467.5 253.5 0.773
Age of onset 21 30 331 0.045*
Educational years 13 16 321.5 0.072
No marker combination
(n= 37)
Marker combination
(n= 13)
χ2(df1) P
Sex (male:female) 29:9 8:2 0.45 (1) 0.503
Clozapine users (yes:no) 5:32 8:5 3.74 (1) 0.053
Language (German:foreign) 30:7 13:0 2.86 (1) 0.091
Handedness (right:left:both) 33:4:0 11:1:1 2.96 (2) 0.227
Statistics represent the comparison of the patient groups with and without the marker combination
CPZ chlorpromazine equivalents (cross-sectional at day of blood drawing), PANSS positive and negative syndrome scale, M mean, SD standard deviation, Mdn median,
df degree of freedom, F F statistic, U Mann–Whitney-U, P p-value
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differentially expressed in tgDISC1 versus littermate
control rats as an animal model for an aberrant signaling
pathway with DISC1 protein involvement. This reverse-
translational approach leads to a unique pairing of a
patient subset, a biological diagnostic marker test, and a
corresponding animal model that likely reﬂects aspects of
an aberrant pathophysiology or brain signaling of that
patient subset.
While we demonstrated that DISC1 overexpression
and misassembly causes the speciﬁc dysregulation of
immune-related gene networks in the tgDISC1 rat,
among them RGS1 and CCL4 transcripts as top hits
decreased in PBMCs, the argument that any marker-
positive patient subset would display DISC1 protein
pathology in their brains cannot be made so far. For
that, we would need a collection of brain samples paired
with PBMC samples, and no such collection is currently
available as it is presently not feasible to visualize DISC1
protein pathology other than by biochemical fractiona-
tion of insoluble DISC1 protein from post mortem brain
samples9.
Alternatively, it would be conceivable that in the RGS1/
CCL4-positive schizophrenia patient subset, signaling
pathways that involve the DISC1 protein are dysregulated
in the brain without DISC1 protein misassembly but
leading to similar changes in PBMC gene expression, either
directly or indirectly through a neuro–immune interaction.
The combination of top markers RGS1/CCL4 was
associated with deﬁcits in cognitive functions in the DSST
that have been repeatedly reported to be impaired in
schizophrenia46,47. The subset detected by the marker
combination also represents patients with a later onset
and less reduced general PANSS score. At this point, we
do not have an explanation why a dysfunctional RGS1/
CCL4 signaling module, possibly linked to aberrant
DISC1 signaling, led to the identiﬁcation of patients with
a less severe disease course. Nevertheless, we observed
that the RGS1/CCL4 marker combination was over-
represented in clozapine users. This could be interesting
for future, more rigorous investigations with much higher
case numbers since a test for RGS1/CCL4 could even-
tually lead to the identiﬁcation of patients non-responsive
to typical dopamine 2-receptor antagonizing drugs, thus
deﬁning treatment resistance48. It is interesting to note
that clozapine itself has immunomodulatory effects and
that the role of these effects on the amelioration of schi-
zophrenia symptoms has not been elucidated49. The
absence of a positive correlation between the medication
at the time of blood drawing and RGS1/CCL4 argues
against an interpretation that the decreased levels of
RGS1/CCL4 could be caused by psychotropic medication
of the schizophrenia patients. Nevertheless, it cannot be
excluded that among the vast number of different psy-
chotropic medications some speciﬁc ones could modulate
the expression of genes listed in Table 1 even though they
were identiﬁed in unmedicated tgDISC1 rats.
We propose to apply testing for RGS1/CCL4 in many
more cases of chronic mental illness, not limited to
schizophrenia, but also to include recurrent affective
disorders and neurological brain diseases to delineate its
diagnostic accuracy. This is not only suggested by the
pleiotropy of effects of DISC1 on clinical psychiatric
phenotypes in particular50 but also by the pleiotropy of
other genetic effects on diverse clinical diagnoses4.
Furthermore, in order to provide diagnostic accuracy,
inclusion of testing against immune-related brain dis-
eases such as multiple sclerosis will be paramount.
Various PBMC gene expression analyses on schizo-
phrenia patients have been published51–53. Interestingly,
a recent meta-analysis also identiﬁed signiﬁcantly
decreased CCL4 gene expression in schizophrenia
patients, as well as other modulated genes from the
same correlated network (see Fig. 2c), but not RGS153.
These gene expression (meta-) analyses were performed
on groups of patients based on a clinical diagnosis which
could dilute out any signiﬁcant marker (combinations)
in subsets. In the hypothesis-guided analysis presented
here, however, a causal model, the tgDISC1 rat, was
used to deﬁne aberrant PBMC signaling that was then
rediscovered in a schizophrenia subset converging on
the marker combination CCL4/RGS1.
It is remarkable that modest overexpression of DISC1
leads to such a profound dysregulation of immune func-
tions (Table 2, Fig. 2). This opens the possibility that apart
from the well-established functions of DISC1 in neuro-
development and synaptic function25, DISC1 plays also a
role in regulating the (neuro-) immune response. Whe-
ther in this function it may also contribute to mental ill-
ness by increasing susceptibility to pathogens or
autoimmune responses remains to be investigated.
The top marker RGS1 is a regulator of G-protein sig-
naling. It is a cytosolic protein located at the inner plasma
membrane, transcribed from chromosome 1q31. RGS1 is
the only reported gene signiﬁcantly changed among the
top markers that is also expressed in the brain, in
microglia cells. On the genetic level, an RGS1 haplotype
has been associated with depression and anxiety54. RGS4,
another member of the RGS family of proteins but not
with high homology in terms of sequence conservation,
has been consistently associated to schizophrenia55. RGS1
single-nucleotide polymorphisms are also associated with
multiple sclerosis56,57, but have not been detected in
GWAS studies of schizophrenia5. It is interesting to note
that a co-regulation database (CORD) analysis58 sees HLA
genes DRA, DPA1, DRB1, and DQB1 as most highly co-
regulated by RGS1. Thus, even though genetic evidence
for involvement of RGS1 in “whole” schizophrenia com-
prising all clinical cases is sparse at this moment, a
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functional link to the major histocompatibility complex
(MHC), the most consistently identiﬁed common variant
in schizophrenia with the highest LOD score5, suggests
that RGS1 itself could well play a so far underappreciated
role in schizophrenia.
RGS1 has also been reported as a prognostic marker in
melanoma or spondylarthritis59,60, indicating that there
are roles for RGS1 in other disease conditions, even
though in the schizophrenia subset its expression seems
to be decreased rather than increased as in those other
diseases. For mental illness diagnostics, it seems therefore
justiﬁed to combine it with a complementary gene, to
constitute a marker signature with high deﬁnition against
those other disease conditions, as done here with CCL4.
One more reasoning argues in favor of a combination of
genes as biomarkers, rather than one single marker alone.
At this point, it is unclear whether in the schizophrenia
patients investigated here, CCL4 expression is decreased
in PBMCs or whether speciﬁc PBMC subpopulations
accountable for its expression are decreased in number.
CCL4 is mainly expressed in NK cells, CD8+ T cells, and
CD14+ monocytes (Supplementary Fig. S6). NKp46, a NK
cell marker, was decreased in cohort II (Supplementary
Fig. S4J), and an analysis of covariance gave a signiﬁcant
inﬂuence of NKp46 level on CCL4 expression. One way to
address the issue of cell number changes would be to
apply ﬂow-cytometry to patient blood. We did not have
access to fresh blood samples and used frozen PBMCs
that have been sampled over a period of time, but by a
deconvolution approach, it has already been shown that
the NK cell population is indeed reduced in schizo-
phrenia, but not bipolar disorder patients61. Nevertheless,
NK cells constitute only 10% of PBMCs, whereas, for
example, CD8+ T cells and CD14+ monocytes constitute
both around 30 and 20% of cells43, respectively, so the
effect of NK cells on CCL4 expression will most likely be
diluted out. Also, in the tgDISC1 rat, no change in NK cell
levels, but nevertheless a signiﬁcant decrease of CCL4
expression in PBMCs was detected. Thus, it seems of less
importance whether one marker captures cell number
effects, as long as the schizophrenia subset identiﬁed by
that marker constitutes one clinically relevant entity, for
example for predicting treatment resistance. Hence, it is
an advantage to combine a minimum of two markers to
rule out non-speciﬁc gene regulatory effects on marker
expression.
As a soluble cytokine in plasma, CCL4 was previously
found elevated in schizophrenia patients62, as were other
proinﬂammatory cytokines, such as interleukin 1β44,
which in this study was not changed when PBMC
expression was investigated (Supplementary Fig. S5G).
This is not in contradiction to our ﬁndings: transcript
expression in cells and half-life time in plasma may follow
a very different kinetics of degradation and, also, there may
be subsets of patients with schizophrenia, such as the 27%
identiﬁed here, that may actually divert from the mean.
In summary, this study has deﬁned a subset of schizo-
phrenia cases with a speciﬁc dysregulation of immune-
related genes and particular clinical characteristics,
inspired by a reverse-translational approach from an
animal model. The main aim of this study was to show a
novel and innovative way as well as a proof-of-concept to
identify subsets of mental illness patients by reverse
translation. Molecular details of DISC1 protein-related
signaling pathways and immune-related genes will need
further elaborations. While more studies are needed to
characterize the RGS1/CCL4-deﬁned schizophrenia sub-
set and its clinical relevance, our here-proposed approach
may prove valuable for changing the diagnostic culture in
clinical psychiatry.
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